Why a 70-Year-Old Peptide Chemistry Firm Is Worth $1.8 Billion

Samsung Biologics is paying a 40% premium over where its target's shares traded before takeover rumors started, to buy a Swiss chemical manufacturer that most people who take a peptide drug have never heard of — and the reason has nothing to do with a new molecule. It's about who can actually make the molecules everyone already wants.

The target, PolyPeptide Group, doesn't discover drugs. It's a contract manufacturer with more than 70 years in the business, built around a chemistry — solid-phase peptide synthesis — that has suddenly become one of the most contested manufacturing capabilities in the pharmaceutical industry, purely because of how much of it the GLP-1 drug boom now requires.

Why making a peptide is its own industry

Small-molecule drugs are built with conventional organic chemistry, a few atoms at a time, in reactors that scale up fairly predictably. Biologics like antibodies are grown inside living cells, which do the molecular assembly themselves. Peptides sit in an awkward, expensive middle: they're chains of amino acids, like small proteins, but they're usually made the way small molecules are — synthetically, not biologically — by building the chain one amino acid at a time on a solid support resin, then washing, cleaving and purifying it, at a scale that for a blockbuster drug means doing that chemistry in multi-thousand-liter reactors with extremely tight specifications. It's capital-intensive, slow to build new capacity for, and not a skill set that a biologics-focused manufacturer or a generic small-molecule plant already has sitting idle. That scarcity, not any single new drug, is what this deal is actually about: one Morgan Stanley analyst, reacting to the announcement, put it plainly in comments reported by Swissinfo: "The peptides drug market is growing rapidly thanks to GLP-1 drugs."

The deal

Samsung Biologics, through its Swiss subsidiary Samsung Peptide, is offering CHF 44.31 per share in cash for PolyPeptide, valuing the company's equity at roughly CHF 1.46 billion (about $1.8 billion), according to a detailed account of the offer terms from Chemanager. That price is 40% above where PolyPeptide's shares traded before acquisition speculation first surfaced, and Swissinfo reported it's being described as the largest M&A deal in South Korea's biopharmaceutical sector to date. PolyPeptide's board unanimously recommended shareholders accept the offer, and Draupnir Holding, which holds roughly 55.65% of shares outstanding, has irrevocably committed to tender its stake — leaving the deal needing acceptance from only a modest further slice of the remaining free float to clear its 66⅔% threshold.

PolyPeptide runs manufacturing and development sites in Sweden, Belgium, France, the US and India, plus an innovation center in Strasbourg. For Samsung Biologics, which built its business making antibodies and antibody-drug conjugates for other drug companies, buying that footprint outright is faster than building equivalent peptide capacity from scratch — Samsung's chief executive, John Rim, said the deal extends the company's "geographic reach and proximity further within the US, Europe and India," per Chemanager's report of the announcement.

What's confirmed, and what's still open

The offer's main acceptance period runs through October 12, 2026, and PolyPeptide has called an extraordinary shareholder meeting for October 26 — though the company's own announcement of that meeting doesn't spell out its agenda or explicitly tie it to the takeover. Regulatory approvals in unspecified jurisdictions are still a stated condition of closing, and none of the coverage found for this story reports that those approvals, or the 66⅔% acceptance threshold itself, have actually been cleared yet. The companies have said they expect the deal to close toward the end of 2026, which leaves real room between where things stand this week and an actual completed acquisition.

It's also worth separating what's confirmed from what's merely plausible. No source found here states which specific drugs PolyPeptide manufactures for which clients — pharmaceutical companies routinely manufacture their own flagship products in-house while using contract manufacturers for secondary supply, generic competition, earlier-stage pipeline work or overflow capacity, and nothing here confirms PolyPeptide's role in any particular approved drug's supply chain. The connection being made, by Samsung and by analysts quoted in this coverage, is to the peptide drug manufacturing market broadly, not to a confirmed, named customer relationship.

What this means for researchers

A manufacturing acquisition like this one won't change any trial result or regulatory decision, and it says nothing about whether any specific drug works. What it does mark is a moment where the unglamorous, purely mechanical side of peptide science — not the biology, not the receptor pharmacology, just the industrial chemistry of actually making the molecule at scale — has become valuable enough to drive a $1.8 billion, 40%-premium, board-unanimous acquisition. For a field that spent decades producing peptide drugs in relatively modest volumes, that's a real inflection point in how much of this chemistry the world now needs built.

It's also a reminder that the supply side of peptide medicine is its own research and engineering problem, separate from drug discovery, with its own bottlenecks, its own capital requirements and now, apparently, its own M&A market. Whether consolidating that capacity into fewer, larger manufacturers makes peptide drugs more reliably available over time, or simply concentrates pricing power in fewer hands, is a question this deal raises but doesn't answer — and one that won't be settled by anything in a tender offer prospectus. Readers who want the general background on how peptide compounds are produced and tested can find it on Torrey Labs' /learn page.